The MeCo Score™ is the first and only clinically validated predictive biomarker test to improve therapy selection for patients with early-stage breast cancer who have a higher risk of relapse yet may benefit from FDA-approved antifibrotic therapy (1,2,3).
In our 130-patient Phase 2 randomized controlled trial, the combined magnitude and duration of survival benefit experienced by High MeCo Score breast cancer patients who received antifibrotic therapy is unprecedented among all other modern targeted therapies ever trialed for breast cancer (3).
Partnerships & Collaborations
Funding
Awards & Affiliations
References
[1] Watson, A.W. et al. (2021). Cell Reports. 29;35(13):109293. doi: 10.1016/j.celrep.2021.109293
[2] Data on file with Cleveland Clinic and MeCo Diagnostics Holdings, Inc.
[3] Quintela-Fandino, M. et al. (2024). Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-24-1518
Note: the prescribing information for the FDA-approved therapy may not include the associated biomarker, and the proposed intended use for the MeCo Score is subject to change.
*The MeCo Score (TM) assay is for Investigational Use Only
and is not cleared or approved by the Food and Drug Administration.
Copyright © 2024 MeCo Diagnostics Holdings, Inc. - All Rights Reserved.